ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO825

ADPKD Calculator: A New Tool to Help in the Detection of Patients with Rapid Progression

Session Information

Category: Genetic Diseases of the Kidneys

  • 1001 Genetic Diseases of the Kidneys: Cystic


  • Mouzo Mirco, Ricardo, Hospital Universitario El Bierzo, Ponferrada, Spain
  • González-Fernández, Juan Antonio, Hospital Universitario El Bierzo, Ponferrada, Spain
  • Simal, Fernando, Hospital Universitario El Bierzo, Ponferrada, Spain
  • Heras Benito, Manuel, Sociedad Castellano Astur Leonesa de Nefrología, Salamanca, Spain
  • Sanchez, Emilio, Sociedad Castellano Astur Leonesa de Nefrología, Salamanca, Spain

Autosomal dominant polycystic kidney disease (ADPKD), a frequent hereditary renal disorder, is the etiology of 10% of t dialysis or renal transplant patients and approximately 70% will progress to end-stage renal disease in the fifth decade of life. In 2016 the ERA-EDTA published the Recommendations for the use of Tolvaptan, that included an Algorithm for the recognition of patients with rapid progression, to assess indications for initiation of treatment in ADPKD patients. Starting from this point, we have developed a new App for free use (Scientifically Endorsed by the SCALN), to facilitate detection of rapid progressions. The aim of this App is calculate variables of Renal Function, Total Renal Volume and by means of an Algorithms and Prediction Models, identify ADPKD patients with Rapid Progression.


Once the conditions of use have been accepted, the patient's data can be entered in various ways. The methods are described in the App itself in "References and Formulas" button as you can see in attached image.


Body Mass Index. Body Surface. Renal Function (Cockroft Gault BMS corrected; MDRD-4; MDRD-4 IDMS; MDRD-6; CKD-EPI; Urine Albumin/Creatinine Ratio; CKD-EPI Cystatin; CKD-EPI Cystatin C Equation).CKD Stage KDIGO 2012 (wiht graphic representation). KIDNEY TOTAL VOLUME with link to Mayo Clinic Website (The user must be previously accepting Mayo Clinic Terms of Use). Identification of Rapid Progressing patients through the use of: 1) the Digitalized Algorithm of the ERA-EDTA Workings Groups cited; and 2) PRO-PKD Prediction Model.


ADPKD Calculator, allows the nephrologist to quickly and easily identify patients as Rapid Progressives, in order to proceed to implement those measures that may slow the progression to ESRD. Finally, the free access to this App from, its availability in multiplatform and English/Spanish languages, facilitates the use of it.